CoChat

Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease

Open access
Horstmann, Solveig, Budig, Leila, Gardner, Humphrey, Koziol, James, Deuschle, Michael, Schilling, Claudia, Wagner, Simone · 2010 · International Psychogeriatrics
Cited by 110

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Deposition of amyloid beta in senile plaques and in cerebral blood vessels is one hallmark of the pathogenesis of Alzheimer's disease (AD). The ability of several matrix metalloproteinases (MMPs) to degrade amyloid precursor protein leading to aggregation of amyloid beta, as well as the increased expression of MMPs in post mortem brain tissue of Alzheimer's patients, indicate that MMPs play an important role in the pathogenesis of AD. METHODS: We investigated levels of MMP-2,-3,-9 and -10 in plasma and cerebrospinal fluid (CSF) of AD patients (n = 14) by gelatin and casein zymography. Comparisons between AD patients and controls relative to levels of MMP-2, MMP-3, MMP-9, and MMP-10 were made with Wilcoxon rank statistics. Pearson correlations were computed as measures of association. RESULTS: MMP-3 in AD was significantly elevated in plasma (p = 0.006) and there was a trend towards increase in CSF (p = 0.05). MMP-2 in CSF of AD patients was significantly decreased (p = 0.02) while levels in plasma remained unchanged. MMP-9 and MMP-10 could not be detected in CSF; MMP-10 was unchanged in plasma, but MMP-9 was significantly decreased (p = 0.02). CONCLUSIONS: These findings constitute further evidence for the important role of MMPs in the pathogenesis of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1041610210000827

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 27

  1. Adair, 2004, Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease, Stroke, 35, e159, 10.1161/01.STR.0000127420.10990.76 · DOI · Paper page
  2. Alvarez-Sabin, 2004, Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome, Stroke, 35, 1316, 10.1161/01.STR.0000126827.69286.90 · DOI · Paper page
  3. Bar-Or, 2003, Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis, Brain, 126, 2738, 10.1093/brain/awg285 · DOI · Paper page
  4. Beuche, 2000, Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis, Neuroreport, 11, 3419, 10.1097/00001756-200011090-00003 · DOI · Paper page
  5. Beyzade, 2003, Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction, Journal of the American College of Cardiology, 41, 2130, 10.1016/S0735-1097(03)00482-0 · DOI
  6. Campbell, 1999, Matrix metalloproteinases and their inhibitors in the nervous system: the good, the bad and the enigmatic, Trends in Neurosciences, 22, 285, 10.1016/S0166-2236(99)01430-7 · DOI
  7. Deb, 2003, Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes, Brain Research, 970, 205, 10.1016/S0006-8993(03)02344-8 · DOI · Paper page
  8. Flex, 2006, Analysis of functional polymorphisms of metalloproteinase genes in persons with vascular dementia and Alzheimer's disease, Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 61, 1065, 10.1093/gerona/61.10.1065 · DOI · Paper page
  9. Helbecque, 2003, The role of matrix metalloproteinase-9 in dementia, Neuroscience Letters, 350, 181, 10.1016/S0304-3940(03)00905-4 · DOI
  10. Helbecque, 2007, Impact of the matrix metalloproteinase MMP-3 on dementia, Neurobiology of Aging, 28, 1215, 10.1016/j.neurobiolaging.2006.05.030 · DOI
  11. Hofman, 1997, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, Lancet, 349, 151, 10.1016/S0140-6736(96)09328-2 · DOI · Paper page
  12. Horstmann, 2003, Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies, Stroke, 34, 2165, 10.1161/01.STR.0000088062.86084.F2 · DOI · Paper page
  13. Lorenzl, 2003, Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases, Journal of the Neurological Science, 207, 71, 10.1016/S0022-510X(02)00398-2 · DOI · Paper page
  14. Lorenzl, 2003, Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease, Neurochemistry International, 43, 191, 10.1016/S0197-0186(03)00004-4 · DOI · Paper page
  15. Lorenzl, 2008, Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia, International Psychogeriatrics, 20, 67, 10.1017/S1041610207005790 · DOI · Paper page
  16. Martin-Aragon, 2009, Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease, Neurochemical Research, 34, 373, 10.1007/s11064-008-9789-3 · DOI
  17. McGeer, 1998, The importance of inflammatory mechanisms in Alzheimer disease, Experimental Gerontology, 33, 371, 10.1016/S0531-5565(98)00013-8 · DOI · Paper page
  18. Montaner, 2001, Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment, Stroke, 32, 1759, 10.1161/01.STR.32.8.1759 · DOI · Paper page
  19. Mrak, 2007, Common inflammatory mechanisms in Lewy body disease and Alzheimer disease, Journal of Neuropathology and Experimental Neurology, 66, 683, 10.1097/nen.0b013e31812503e1 · DOI · Paper page
  20. Pollanen, 2002, Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki Sudden Death Study, Atherosclerosis, 164, 329, 10.1016/S0021-9150(02)00107-7 · DOI
  21. Pollanen, 2005, Matrix metalloproteinase3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques, Atherosclerosis, 180, 73, 10.1016/j.atherosclerosis.2004.10.041 · DOI
  22. Pozzi, 2000, Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization, Proceedings of the National Academies of Sciences, 97, 2202, 10.1073/pnas.040378497 · DOI · Paper page
  23. Reitz, 2008, Matrix metalloproteinase 3 haplotypes and dementia and Alzheimer's disease: the Rotterdam Study, Neurobiology of Aging, 29, 874, 10.1016/j.neurobiolaging.2007.01.001 · DOI
  24. Roher, 1994, Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A, Biochemical and Biophysical Research Communication, 205, 1755, 10.1006/bbrc.1994.2872 · DOI · Paper page
  25. Saarela, 2004, Interaction between matrix metalloproteinase 3 and the epsilon4 allele of apolipoprotein E increases the risk of Alzheimer's disease in Finns, Neuroscience Letters, 367, 336, 10.1016/j.neulet.2004.06.027 · DOI
  26. Thorns, 2003, Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas, Anticancer Research, 23, 3937
  27. Woessner, 1991, Matrix metalloproteinases and their inhibitors in connective tissue remodeling, FASEB Journal, 5, 2145, 10.1096/fasebj.5.8.1850705 · DOI · Paper page

Cited by

See all 110

Metadata

Authors
Horstmann, S., Budig, L., Gardner, H., Koziol, J., Deuschle, M., Schilling, C., & Wagner, S.
Venue
International Psychogeriatrics
Publisher
Elsevier BV
Published
2010-09
Volume
22
Issue
6
Pages
966-972
ISSN
1041-6102 (ISSN-L)
OpenAlex
W2129034908
Cited by
110
References
3
FWCI
3.42
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. https://app.cochat.ai/papers/10.1017/s1041610210000827
The paper
Horstmann, S., Budig, L., Gardner, H., Koziol, J., Deuschle, M., Schilling, C., & Wagner, S. (2010). Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. International Psychogeriatrics. https://doi.org/10.1017/s1041610210000827

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.